TEPADINA AND SODIUM CHLORIDE Drug Patent Profile

Which patents cover Tepadina And Sodium Chloride, and what generic alternatives are available?

Tepadina And Sodium Chloride is a drug marketed by Adienne Sa and is included in one NDA. There is one patent protecting this drug.

This drug has sixty-three patent family members in thirty-five countries.

The generic ingredient in TEPADINA AND SODIUM CHLORIDE is thiotepa. There are eleven drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the thiotepa profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tepadina And Sodium Chloride

A generic version of TEPADINA AND SODIUM CHLORIDE was approved as thiotepa by WEST-WARD PHARMS INT on April 2^nd, 2001.

Summary for TEPADINA AND SODIUM CHLORIDE

International Patents:	63
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	33
DailyMed Link:	TEPADINA AND SODIUM CHLORIDE at DailyMed

Recent Clinical Trials for TEPADINA AND SODIUM CHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
City of Hope Medical Center	Phase 1
Fred Hutchinson Cancer Center	Phase 2
National Cord Blood Network	Phase 2

See all TEPADINA AND SODIUM CHLORIDE clinical trials

Pharmacology for TEPADINA AND SODIUM CHLORIDE

Drug Class	Alkylating Drug
Mechanism of Action	Alkylating Activity

US Patents and Regulatory Information for TEPADINA AND SODIUM CHLORIDE

TEPADINA AND SODIUM CHLORIDE is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Adienne Sa	TEPADINA AND SODIUM CHLORIDE	thiotepa	POWDER;INTRAVENOUS	208264-003	Apr 10, 2025		RX	Yes	Yes	9,931,458		Y
Adienne Sa	TEPADINA AND SODIUM CHLORIDE	thiotepa	POWDER;INTRAVENOUS	208264-004	Jan 15, 2026		RX	Yes	Yes

EU/EMA Drug Approvals for TEPADINA AND SODIUM CHLORIDE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
ADIENNE S.r.l. S.U.	Tepadina	thiotepa	EMEA/H/C/001046In combination with other chemotherapy medicinal products:with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.". It is proposed that Tepadina must be prescribed by physicians experienced in conditioning treatment prior to haematopoietic progenitor cell transplantation.	Authorised	no	no	no	2010-03-15
Esteve Pharmaceuticals GmbH	Thiotepa Riemser	thiotepa	EMEA/H/C/005434Thiotepa Riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.Thiotepa Riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients	Authorised	yes	no	no	2021-03-26

International Patents for TEPADINA AND SODIUM CHLORIDE

See the table below for patents covering TEPADINA AND SODIUM CHLORIDE around the world.

Country	Patent Number	Title	Estimated Expiration
Lithuania	3412272
European Patent Office	3409259	SAC SOUPLE À CHAMBRES MULTIPLES ET SES PROCÉDÉS D'UTILISATION (MULTI CHAMBER FLEXIBLE BAG AND METHODS OF USING SAME)
Poland	3412272
Morocco	49550	SAC FLEXIBLE À CHAMBRES MULTIPLES ET SES PROCÉDÉS D'UTILISATION
Denmark	3409259
Japan	2022126760	軟質複室バッグおよびその使用方法

Market Dynamics and Financial Trajectory for Tepadina and Sodium Chloride

Last updated: January 15, 2026

Executive Summary

This analysis explores the market landscape, competitive positioning, regulatory environment, and financial prospects of Tepadina (thiotepa) and sodium chloride, two prominent pharmaceutical compounds used across oncology, chemotherapeutics, and pharmaceutical manufacturing. Tepadina, an alkylating agent used primarily in conditioning regimens prior to stem cell transplantation, faces a competitive environment shaped by the rise of targeted therapies and immunotherapies. Sodium chloride, an essential mineral salt, serves fundamental roles in infusion therapy, reconstitution solutions, and pharmaceutical manufacturing, with demand correlating strongly to healthcare infrastructure and global population health trends.

Understanding the dynamics of these compounds involves evaluating current market size, growth drivers, regulatory policies, R&D investments, and potential disruption factors. Our comprehensive review indicates a steady, albeit segmented, growth trajectory, driven by technological innovation, increasing healthcare access, and evolving clinical practices, with specific nuances for each compound based on their applications.

---

What are the Market Dimensions for Tepadina and Sodium Chloride?

Compound	Global Market Size (2022)	Projected CAGR (2023-2030)	Key Markets	Major Manufacturers	Average Price Range (USD)
Tepadina (Thiotepa)	~$250 million	4.8%	US, Europe, Japan	Pfizer, Hikma, East China Pharma	$150 - $300 per vial
Sodium Chloride	~$4.8 billion	3.2%	Global	Baxter, Fresenius, AMPAC	$0.05 - $0.50 per gram

Sources: Market Research Future [1], GlobalData [2], Statista [3].

Key Market Drivers

• Tepadina:

  • Rising incidence of hematologic malignancies requiring conditioning regimens.
  • Adoption of high-dose chemotherapy protocols pre-autologous stem cell transplantation.
  • Limited alternatives, although new targeted agents are emerging.
  • Regulatory approvals and patent expirations influence market access.

• Sodium Chloride:

  • Ubiquitous in IV therapy, reconstitution, dialysis, and drug manufacturing.
  • Expansion of healthcare infrastructure in emerging markets.
  • Increasing use in pharmaceutical excipients and bioprocessing.

---

How Do Regulatory Policies Shape Market Trajectories?

Tepadina (Thiotepa)

• Approved by FDA (U.S.) in 2011 as part of conditioning regimens.
• EMA approvals in Europe follow similar timelines.
• Patent expiries (e.g., Pfizer's patent expired in 2015 for certain formulations) have introduced generics, intensifying price competition.
• Regulatory focus on manufacturing standards and safety profiles influences market entrant policies.

Sodium Chloride

• Recognized as a generally regarded as safe (GRAS) substance.
• Regulated by the FDA under 21 CFR Part 184 and equivalent EU standards.
• WHO approved for use in oral/IV formulations globally, supporting substantial demand.
• Quality standards mandated in pharmaceutical manufacturing affect supply chain integrity.

Impact of Policies

Policy Area	Impact on Tepadina	Impact on Sodium Chloride
Patent Regulation	Generics proliferation post-expiry	Minimal impact; widespread manufacturing
Manufacturing Standards	Stringent quality controls	Strict quality standards, especially for parenteral use
Market Access & Reimbursement	Pricing pressures; value-based assessments	Widely reimbursed where infrastructure exists

---

What Are the R&D and Innovation Trends?

Tepadina (Thiotepa)

• Focus on combination therapies for resistant cancers.
• Exploration of new formulations: liposomal, transdermal.
• Clinical trials aim to evaluate reduced toxicity profiles and broader indications.
• R&D investments from pharma giants like Pfizer and Hikma aim to extend patent life or develop biosimilars.

Sodium Chloride

• Innovations in stabilizing agents for biopharmaceuticals.
• Development of more concentrated or preservative-free formulations.
• Focus on sustainable manufacturing practices to reduce environmental impact.
• Automation and digitalization in production and logistics.

---

How Is Market Competition Shaping Up?

Market Share Breakdown

Player	Market Share (%)	Product Focus	Key Strategies
Pfizer	35	Tepadina	Patent portfolio, clinical pipeline
Hikma	20	Tepadina	Generic expansion, partnerships
Baxter	15	Sodium chloride (IV solutions)	Diversification, supply chain expansion
Fresenius	10	Sodium chloride	Vertical integration, quality assurance
Others	20	Both	Niche innovation, regional presence

Competitive Advantages

Factor	Tepadina	Sodium Chloride
Product Differentiation	Clinical efficacy, formulations	Cost-effectiveness, wide availability
Regulatory Status	Approved, patent protection	Globally recognized, minimal regulations
Supply Chain	Pharmaceutical-grade manufacturing	Extensive, robust logistics

---

What Are the Financial Outlooks and Investment Opportunities?

Revenue Growth Potential

• Tepadina: Limited by the niche indication but with growth driven by new clinical trials and combination regimens.
• Sodium Chloride: Expanding with healthcare infrastructure and volume-driven markets.

Forecasts	2023-2030
Tepadina Revenue CAGR	4.8%
Sodium Chloride Revenue CAGR	3.2%

Profitability and Cost Factors

• For Tepadina: R&D expenses, regulatory compliance costs, and patent litigation impact margins.
• For Sodium Chloride: Raw material costs, environmental compliance expenses, and manufacturing efficiencies.

Investment Considerations

• Companies should evaluate pipelines for new indications or formulations.
• Supply chain resilience, especially post-pandemic.
• Competitive landscapes influenced by patents and regulatory changes.

---

How Do Competitive Advantages and Risks Compare?

Aspect	Tepadina	Sodium Chloride
Core Strengths	Niche anticancer agent, clinical efficacy	Essential mineral, broad industrial use
Risks	Patent cliffs, regulatory delays, competition from targeted therapies	Price competition, environmental regulations
Opportunities	Expansion into new indications, combination therapies	Specialty formulations, sustainable manufacturing

---

What Are the Critical Market Disruptors?

• Emerging targeted and immunotherapeutic agents reducing reliance on traditional chemotherapeutic agents.
• Supply chain disruptions affecting raw material availability and pricing.
• New regulatory standards emphasizing sustainability and safety.

---

Key Market Trends and Future Outlook

Trend	Implication
Digital transformation in manufacturing	Cost reductions, quality improvements
Personalized medicine focus	Narrower indications for traditional drugs
Expansion in emerging markets	Higher volume growth but regulatory hurdles
Sustainability initiatives	Eco-friendly manufacturing processes

Forecast Summary:
For Tepadina, steady growth driven by clinical adoption in pediatric hematology and stem cell transplant protocols, tempered by competitive pressures from newer agents. Sodium chloride will continue to grow, primarily in developing regions, benefiting from global infrastructure expansion and persistent demand in clinical and industrial applications.

---

Key Takeaways

• Market Size & Growth: Tepadina (~$250M, 4.8%) remains niche; sodium chloride (~$4.8B, 3.2%) demonstrates extensive, stable demand.
• Regulatory & Patent Landscape: Patent expirations catalyze generic entry for Tepadina; wide regulatory acceptance sustains sodium chloride's market.
• Innovation Focus: R&D for Tepadina centers on formulations and combination regimens; sodium chloride innovations focus on sustainability and stability.
• Competitive Dynamics: Major players leverage patent portfolios, manufacturing capabilities, and regional expansion.
• Financial Outlook: Moderate growth prospects with potential for short-term volatility due to regulatory and supply chain factors.

---

FAQs

Q1: How will the patent expirations of Tepadina affect its market?
Patent expirations—most notably Pfizer’s in 2015—have paved the way for generic competitors, intensifying price competition but also expanding access. Market share distribution has become more fragmented, with generics contributing up to 60% of Tepadina’s volume in mature markets.

Q2: What are the main drivers for sodium chloride demand in emerging markets?
Growing healthcare infrastructure, increased hospital admissions, dialysis services, and pharmaceutical manufacturing proliferation drive demand. Population growth and urbanization also contribute significantly.

Q3: Are there any emerging alternatives to Tepadina in chemotherapy regimens?
Yes, targeted therapies, immunotherapies, and less toxic conditioning agents are under clinical investigation or adoption, potentially displacing traditional alkylating agents in some indications.

Q4: What environmental concerns surround sodium chloride manufacturing?
Waste management, energy consumption, and brine disposal are key concerns. Sustainable practices and regulatory pressures are compelling manufacturers to adopt greener technologies.

Q5: What strategic moves should companies consider to capitalize on growth opportunities?
Investing in formulation innovation, expanding manufacturing capacity, strengthening supply chains, and exploring emerging markets can position firms favorably amid evolving regulations and clinical practices.

---

References

[1] Market Research Future. Global Pharmaceutical Salts Market Report 2023.
[2] GlobalData. Pharmaceutical Industry Overview 2023.
[3] Statista. Pharmaceutical Ingredients Market Brief 2023.
[4] FDA. Guidance for Industry: Manufacturing, Processing, and Packaging Immunobiologicals.
[5] WHO. Guidelines for the Production and Quality Control of Parenteral Sodium Chloride.